Tesamorelin

Stabilized GHRH analog (Egrifta) — FDA-approved for visceral fat reduction in HIV lipodystrophy.

Tesamorelin is the most clinically proven member of the GHRH family — an actual approved drug (Egrifta) with real trial data, originally for shrinking the deep visceral fat that builds up in HIV patients on older medications. That visceral-fat effect is exactly what makes it interesting to everyone else: it's one of the few peptides shown to target the dangerous fat packed around your organs rather than just the soft fat under the skin. It also raises IGF-1 and has shown cognitive signals in mild-cognitive-impairment trials. Stronger and far better documented than Sermorelin, it's the GHRH of choice when fat loss is the real goal.

Dose

1–2 mg subQ daily.

Reconstitute

20 mg + 2 mL = 10 mg/mL. 10 units = 1 mg.

Schedule

5–7×/week, 12+ week cycles.

Half-life

~30 minutes injected (downstream IGF-1 elevation lasts longer).

Timing

Pre-bed fasted, or AM fasted.

Risks

Water retention, joint aches, glucose intolerance at high doses, carpal-tunnel symptoms. Monitor IGF-1 if running long.

Educational reference — not medical advice. Many peptides are not approved for the uses discussed; verify status in your jurisdiction and decide anything here with a qualified clinician.

within Growth Hormone — Natural Release (Secretagogues)